BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market
BioHarvest Sciences has received approval to list its common shares on the Nasdaq Global Market. Trading will commence on November 12th, 2024, under the symbol 'BHST'. The company's shares will continue trading on the OTCQB until market close on November 11th, 2024, while maintaining its listing on the Canadian Securities Exchange (CSE). This uplisting represents a significant milestone aimed at expanding the company's shareholder base, improving liquidity, and enhancing its public profile.
BioHarvest Sciences ha ricevuto l'approvazione per quotare le proprie azioni ordinarie sul Nasdaq Global Market. Le contrattazioni inizieranno il 12 novembre 2024, con il simbolo 'BHST'. Le azioni dell'azienda continueranno a essere negoziate sull'OTCQB fino alla chiusura del mercato l'11 novembre 2024, mantenendo al contempo la sua quotazione sulla Canadian Securities Exchange (CSE). Questo passaggio rappresenta un traguardo significativo volto ad espandere la base di azionisti dell'azienda, migliorare la liquidità e aumentare il suo profilo pubblico.
BioHarvest Sciences ha recibido la aprobación para listar sus acciones comunes en el Nasdaq Global Market. La negociación comenzará el 12 de noviembre de 2024, bajo el símbolo 'BHST'. Las acciones de la compañía continuarán negociándose en el OTCQB hasta el cierre del mercado el 11 de noviembre de 2024, manteniendo su cotización en la Canadian Securities Exchange (CSE). Este ascenso representa un hito significativo destinado a expandir la base de accionistas de la compañía, mejorar la liquidez y aumentar su perfil público.
BioHarvest Sciences는 Nasdaq Global Market에 자사의 보통주 상장을 승인받았습니다. 거래는 2024년 11월 12일 'BHST' 기호로 시작될 예정입니다. 회사의 주식은 2024년 11월 11일 시장 종료 시까지 OTCQB에서 계속 거래되며, 캐나다 증권 거래소(CSE)에서의 상장은 유지됩니다. 이번 상장은 회사의 주주 기반을 확장하고 유동성을 개선하며 공공 이미지를 강화하는 것을 목표로 하는 중요한 이정표입니다.
BioHarvest Sciences a reçu l'approbation pour inscrire ses actions ordinaires sur le Nasdaq Global Market. Les négociations commenceront le 12 novembre 2024, sous le symbole 'BHST'. Les actions de l'entreprise continueront d'être négociées sur l'OTCQB jusqu'à la fermeture du marché le 11 novembre 2024, tout en maintenant son inscription à la Bourse des valeurs mobilières canadienne (CSE). Cette nouvelle cotation représente une étape importante visant à élargir la base d'actionnaires de l'entreprise, à améliorer la liquidité et à renforcer son profil public.
BioHarvest Sciences hat die Genehmigung erhalten, ihre Stammaktien am Nasdaq Global Market zu listen. Der Handel beginnt am 12. November 2024 unter dem Symbol 'BHST'. Die Aktien des Unternehmens werden bis zum Marktabschluss am 11. November 2024 weiterhin am OTCQB gehandelt, während die Notierung an der Canadian Securities Exchange (CSE) beibehalten wird. Diese Auflistung stellt einen bedeutenden Meilenstein dar, der darauf abzielt, die Aktionärsbasis des Unternehmens zu erweitern, die Liquidität zu verbessern und das öffentliche Profil zu stärken.
- Uplisting to Nasdaq Global Market, providing access to larger investor base
- Potential for improved stock liquidity through Nasdaq listing
- Maintaining dual listing on CSE, offering trading flexibility
- None.
Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 7, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Nasdaq Stock Market LLC has approved the listing of the Company's common shares on the Nasdaq Global Market ("Nasdaq").
The Company expects to begin trading on the Nasdaq on Tuesday, November 12th, 2024, under the new symbol "BHST". The company's common shares will trade on the OTCQB until market close on November 11th, 2024, and will continue to trade on the Canadian Securities Exchange ("CSE").
Dr. Zaki Rakib, Chairman of BioHarvest Sciences, said: "We are pleased to announce the listing of our shares on the Nasdaq, representing a significant capital markets milestone for BioHarvest Sciences and our valued shareholder partners. We believe this listing will serve to expand our potential shareholder base, improve liquidity and elevate our public profile in the industry - ultimately helping to enhance long-term shareholder value creation."
Ilan Sobel, Chief Executive Officer of BioHarvest Sciences, concluded: "I am incredibly proud of the efforts of the whole team at BioHarvest, whose operational execution has positioned us to list on a senior U.S. exchange and tap into a global shareholder base. We look forward to our first day of trading on the Nasdaq on Tuesday, November 12, 2024. I would like to thank our valued shareholder partners, whose significant support has played an important role in our continued success."
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
(604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
BHSC@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229158
FAQ
When will BioHarvest Sciences (CNVCF) start trading on Nasdaq?
What will happen to BioHarvest Sciences' (CNVCF) OTCQB listing?
Will BioHarvest Sciences (CNVCF) maintain its CSE listing after uplisting to Nasdaq?
